H H Thijssen

Summary

Affiliation: Maastricht University
Country: The Netherlands

Publications

  1. ncbi request reprint Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes
    H H Thijssen
    Department of Pharmacology, University of Maastricht, The Netherlands
    Drug Metab Dispos 28:1284-90. 2000
  2. ncbi request reprint Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3
    H H Thijssen
    Department of Pharmacology, Cardiovascular Research Institute, University of Maastricht, The Netherlands
    Clin Pharmacol Ther 70:292-8. 2001
  3. ncbi request reprint Menaquinone-4 in breast milk is derived from dietary phylloquinone
    H H W Thijssen
    Department of Pharmacology, University of Maastricht, The Netherlands
    Br J Nutr 87:219-26. 2002
  4. ncbi request reprint Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype
    Henk H W Thijssen
    Department of Pharmacology, Cardiovascular Research Institute Maastricht, University of Maastricht, The Netherlands
    Clin Pharmacol Ther 74:61-8. 2003
  5. ncbi request reprint Menadione is a metabolite of oral vitamin K
    Henk H W Thijssen
    Department of Pharmacology, Cardiovascular Research Institute Maastricht, University of Maastricht, PO Box 616, 6200 MD Maastricht, The Netherlands
    Br J Nutr 95:260-6. 2006
  6. pmc Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics
    J J Hermans
    Cardiovascular Research Institute Maastricht, Department of Pharmacology, University of Limburg, Maastricht, The Netherlands
    Br J Pharmacol 110:482-90. 1993
  7. pmc Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data
    J N de Hoon
    Department of Pharmacology and Toxicology, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
    Br J Clin Pharmacol 52:45-51. 2001
  8. ncbi request reprint Pharmacogenetics of acenocoumarol pharmacodynamics
    Sandrine Morin
    Pharmacology Department, Saint Antoine University Hospital, Paris, France
    Clin Pharmacol Ther 75:403-14. 2004

Collaborators

Detail Information

Publications8

  1. ncbi request reprint Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes
    H H Thijssen
    Department of Pharmacology, University of Maastricht, The Netherlands
    Drug Metab Dispos 28:1284-90. 2000
    ..Drug interactions must be expected, particularly for drugs interfering with CYP2C9. Also, drugs interfering with CYP1A2 and CYP2C19 may potentiate acenocoumarol anticoagulant therapy...
  2. ncbi request reprint Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3
    H H Thijssen
    Department of Pharmacology, Cardiovascular Research Institute, University of Maastricht, The Netherlands
    Clin Pharmacol Ther 70:292-8. 2001
    ..Our objective was to study the pharmacokinetics of R - and S -acenocoumarol in a subject who was highly sensitive to the anticoagulant effect of acenocoumarol. The subject was found to be heterozygous for CYP2C9*3...
  3. ncbi request reprint Menaquinone-4 in breast milk is derived from dietary phylloquinone
    H H W Thijssen
    Department of Pharmacology, University of Maastricht, The Netherlands
    Br J Nutr 87:219-26. 2002
    ..Phylloquinone supplementation to lactating mothers may be of benefit to the newborn infant, since both phylloquinone and menaquinone-4 are raised by supplementation...
  4. ncbi request reprint Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype
    Henk H W Thijssen
    Department of Pharmacology, Cardiovascular Research Institute Maastricht, University of Maastricht, The Netherlands
    Clin Pharmacol Ther 74:61-8. 2003
    ..Patients with the CYP2C9*3 variant are known to require a lower maintenance dose of racemic acenocoumarol. We investigated the impact of the polymorphisms CYP2C9*2 and CYP2C9*3 on the pharmacokinetics of R- and S-acenocoumarol...
  5. ncbi request reprint Menadione is a metabolite of oral vitamin K
    Henk H W Thijssen
    Department of Pharmacology, Cardiovascular Research Institute Maastricht, University of Maastricht, PO Box 616, 6200 MD Maastricht, The Netherlands
    Br J Nutr 95:260-6. 2006
    ..The observations make it likely that part of the menaquinone-4 in tissues results from uptake and prenylation of circulating menadione...
  6. pmc Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics
    J J Hermans
    Cardiovascular Research Institute Maastricht, Department of Pharmacology, University of Limburg, Maastricht, The Netherlands
    Br J Pharmacol 110:482-90. 1993
    ..The 7-hydroxylation of R/S acenocoumarol and the 6-hydroxylation of S-acenocoumarol are at least partly conducted by (a) P450 isozyme(s) of the 2C subfamily different from P450 2C9 (the main S-warfarin 7- and 6-hydroxylase)...
  7. pmc Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data
    J N de Hoon
    Department of Pharmacology and Toxicology, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands
    Br J Clin Pharmacol 52:45-51. 2001
    ..To investigate the peripheral vascular effects and pharmacokinetics of dihydroergotamine (DHE) 0.5 mg after a single subcutaneous administration in humans...
  8. ncbi request reprint Pharmacogenetics of acenocoumarol pharmacodynamics
    Sandrine Morin
    Pharmacology Department, Saint Antoine University Hospital, Paris, France
    Clin Pharmacol Ther 75:403-14. 2004
    ..The aim of this study was to investigate the respective contribution of the different cytochrome P450 (CYP) 2C9 genetic polymorphisms to the interindividual variability of acenocoumarol pharmacodynamic response...